Article

Antiviral T-cell Biofactory platform for SARS-CoV-2

2022-06-27

Abstract excerpt

1.0 <h4> A bstract </h4> Vaccines help reduce new infections, but interventions that can prevent the disease from transitioning to a severe stage are rather limited. Dysregulated IFN kinetics are mostly exploited by pathogenic viruses, including SARS-CoV-2. The clinical benefits of systemically infused IFN are, unfortunately, mired by undesired side effects. To address this situation, we engineered a T cell to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 652228fa-0f3e-5d09-a9a1-fb463f26a1ff
DOI: 10.1101/2022.06.26.497669

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Antiviral T-cell Biofactory platform for SARS-CoV-2DOI 10.1101/2022.06.26.497669Read

Development of an in vitro method to assess the immunogenicity of biologics in the prevention of infectious diseasesSemantic proximity Read

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopSemantic proximity Read

Synthetic rewiring and boosting type I interferon responses for visualization and counteracting viral infectionsSemantic proximity Read

Highly-sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodiesSemantic proximity Read

Human type-I interferon omega holds potent antiviral properties and promotes cytolytic CD8 <sup>+</sup> T cell responsesSemantic proximity Read

Nasally-delivered interferon-λ protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including OmicronSemantic proximity Read

Kinetically activating nanovaccine mimicking multidimensional immunomodulation of natural infection for broad protection against heterologous viruses in animal modelsSemantic proximity Read

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV.Semantic proximity Read

Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunitySemantic proximity Read

RNA-based vaccines and innate immune activation: Not too hot and not too coldSemantic proximity Read

Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment EfficacySemantic proximity Read

Infection-Simulator, Immunostimulatory and Immunomodulatory Effects of Interferons I and III in Biological Systems: A New Era in Vaccinology and Therapeutics Possible?Semantic proximity Read